In a nutshell This trial was carried out to assess the effectiveness R-FND (rituximab, fludarabine, mitoxantrone, and dexamethasone) followed by ibritumomab tiuxetan (YIT; Zevalin) radioimmunotherapy (RIT), and rituximab maintenance therapy in patients with untreated high-risk follicular...
Read More
In a nutshell This study was carried out to assess the risk of fractures associated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) for diffuse large B-cell lymphoma (DLBCL). The authors found that there was a high fracture risk in older patients receiving R-CHOP for the treatment of...
Read More
In a nutshell The study evaluated how characteristics of CAR-T cell infusion (CTCI) products impact their effectiveness and toxicity in patients with large B cell lymphoma (LBCL). The authors found that diversity in molecular and cellular features of CTCI products caused variations in efficacy and toxicity after axicabtagene-ciloleucel (axi-cel;...
Read More
In a nutshell This study will evaluate a three-drug regimen for the treatment of relapsed B-cell non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL). The primary outcomes are how many patients respond to treatment or have a complete response (cancer no longer detectable). The study will take place in the United States. The details B-cell...
Read More
In a nutshell This study will evaluate the antibody therapy odronextamab for patients with relapsed B-cell non-Hodgkin lymphoma (NHL). The primary outcomes will be how many patients respond to treatment, and how many have a complete response (cancer no longer detectable). The details For B-cell NHL which has relapsed (returned) after...
Read More
In a nutshell This review provided updates to the NCCN guidelines for pediatric aggressive mature B-Cell lymphomas. Some background Pediatric aggressive mature B-cell lymphomas are the most common types of non-Hodgkin lymphoma (NHL) in children. They include Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). These diseases are...
Read More
In a nutshell The study evaluated the safety and effectiveness of 177Lu-lilotomab satetraxetan (177LLS; Betalutin) in patients with relapsed/refractory (r/r) indolent non-Hodgkin lymphoma (iNHL). The main finding was that 177LLS was proven to be a valuable alternative treatment in such patients. Some background NHL is a type of lymphoma that spreads...
Read More
In a nutshell This study aimed to investigate the association between total body irradiation and further breast cancer diagnosis in patients treated with blood or marrow transplantation for leukemia-lymphoma. This study concluded that there is an association between the total body irradiation and an increased risk of breast cancer in certain...
Read More
In a nutshell This study was carried out to assess the outcomes of pregnant women who have non-Hodgkin lymphoma (NHL). The authors concluded that treating NHL with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like regimens during pregnancy can be considered after the first trimester. Some background NHL...
Read More
In a nutshell This study examined the effectiveness of complete surgical removal of aggressive non-Hodgkin lymphoma (NHL). The authors found that in young patients with diffuse large B-cell lymphoma (DLBCL) may benefit from complete surgical removal of the tumor before immunochemotherapy (ICT). Some background Lymphoma is a cancer that...
Read More
In a nutshell This study aimed to investigate the long-term effectiveness of the combination of ibrutinib, bendamustine, and rituximab in relapsed/unresponsive chronic lymphocytic leukemia/small lymphocytic lymphoma. This study concluded that this combination was safe and effective in the long-term in these patients. Some background...
Read More
In a nutshell This study will evaluate the best dose of idelalisib (Zydelig) for patients with relapsed follicular lymphoma (FL). The primary outcomes are overall response and side effects. The details FL is a slow-growing cancer of B-cells, a type of white blood cell. Idelalisib is a medication that inhibits certain proteins involved in...
Read More
